0001104659-23-009465.txt : 20230201 0001104659-23-009465.hdr.sgml : 20230201 20230201214105 ACCESSION NUMBER: 0001104659-23-009465 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230201 DATE AS OF CHANGE: 20230201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAGNONI PABLO J CENTRAL INDEX KEY: 0001205703 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38586 FILM NUMBER: 23578618 MAIL ADDRESS: STREET 1: ONYX PHARMACEUTICALS, INC. STREET 2: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 tm235103-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-02-01 0 0001709401 Rubius Therapeutics, Inc. RUBY 0001205703 CAGNONI PABLO J C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON ST. FOXBOROUGH MA 02035 1 0 0 0 Common Stock 2023-02-01 4 S 0 8448 0.25 D 66082 D Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. /s/ Jennifer Kamocsay, attorney-in-fact 2023-02-01